In the second half of 2009, Sinovac Biotech was reporting blockbuster revenues because its flu vaccine sales went through the roof, as China faced the specter of a swine flu (H1N1) epidemic. This year, things are different. The public is not being inundated with daily news reports of flu deaths or increasing numbers of flu cases. And there isn’t any ensuing rush on the part of the general public to inoculate themselves from a potentially lethal dose of flu. It's not surprising that the company's stock has sold lower.  More details...

Stock Symbol: (NSDQ: SVA)